masitinib

a protein kinase inhibitor and antineoplastic agent

Also Known As:

4-((4-methylpiperazin-1-yl)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)-1,3-thiazol-2-yl)amino)phenyl)benzamide; AB 1010; AB-1010; AB1010; Kinavet; Kinavet CA-1; Masican; Masivet; Masiviera; masatinib; masitinib mesilate; masitinib mesylate; masitinib methanesulfonate

Networked: 98 relevant articles (13 outcomes, 31 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hermine, Olivier: 23 articles (01/2022 - 01/2009)
2.	Moussy, Alain: 19 articles (01/2022 - 01/2009)
3.	Dubreuil, Patrice: 17 articles (01/2020 - 01/2009)
4.	Hermine, O: 10 articles (01/2018 - 11/2008)
5.	Mansfield, Colin D: 9 articles (01/2022 - 01/2009)
6.	Moussy, A: 8 articles (01/2018 - 11/2008)
7.	Mansfield, Colin: 5 articles (01/2022 - 01/2015)
8.	Dubreuil, P: 5 articles (06/2015 - 11/2008)
9.	Ranieri, Girolamo: 4 articles (01/2021 - 07/2014)
10.	Kinet, Jean-Pierre: 4 articles (01/2020 - 07/2010)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2010 - ""Masitinib" is safe and effective for the treatment of canine mast cell tumors." 11/01/2008 - "Masitinib is safe and effective at delaying tumor progression in dogs presenting with recurrent or nonresectable grade II or III nonmetastatic MCT." 11/01/2008 - "Masitinib is safe and effective for the treatment of canine mast cell tumors." 09/15/2022 - "In humans, however, the antitumor efficacy of masitinib was found to be attenuated against tumor cells with mutations of the c-kit gene. " 09/01/2009 - "This dose-escalation study was conducted in patients with advanced and/or metastatic cancer to determine the maximum tolerated dose (MTD) for orally administered masitinib over a 12-week period. "
2.	Mastocytosis 01/01/2011 - "Masitinib could therefore be a useful treatment for mastocytosis patients with depression and anxiety symptoms." 12/01/2010 - "Masitinib is a promising treatment for indolent forms of mastocytosis with handicap and indicates acceptable tolerability for long-term treatment regimens." 01/01/2011 - "In conclusion, depression is very frequent in mastocytosis patients and masitinib therapy is associated with the reduction its psychic experiences. " 01/01/2011 - "Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy." 01/01/2011 - "Our objective was to determine the prevalence and to describe features of depression in a large cohort of mastocytosis patients (n = 288) and to investigate the therapeutic impact of the protein kinase inhibitor masitinib in depression symptoms. "
3.	Asthma (Bronchial Asthma) 01/01/2012 - "Masitinib deserves further study in humans with chronic allergic asthma." 01/01/2022 - "Orally administered masitinib reduces the risk of asthma exacerbations in severe asthma patients, with an acceptable safety profile. " 08/01/2009 - "Despite this similar reduction, the Asthma Control Questionnaire score was significantly better in the masitinib arm as compared to placebo with a reduction by 0.99 unit at week 16 (P < 0.001) vs 0.43 unit in the placebo arm. " 01/01/2012 - "We hypothesized masitinib would decrease airway eosinophilia and consequently improve pulmonary mechanics in a feline allergic asthma model. " 01/01/2022 - "Masitinib may potentially provide a new treatment option for oral corticosteroid-dependent severe asthma."
4.	Lymphoma (Lymphomas) 08/01/2016 - "In conclusion, masitinib is effective in treating canine epitheliotropic lymphoma. " 08/01/2016 - "This study evaluated efficacy and side effects of masitinib in canine epitheliotropic lymphoma. " 12/01/2013 - "Therefore, this study aimed to assess the potential of masitinib to revert MDR in canine malignant lymphoma using an in vitro model with canine lymphoid cell lines. " 08/01/2016 - "Masitinib monotherapy in canine epitheliotropic lymphoma." 12/01/2013 - "The current findings provide the rationale for a combined use of masitinib with doxorubicin in the treatment of dogs with doxorubicin-resistant malignant lymphoma but await confirmation in clinical trials. "
5.	Melanoma (Melanoma, Malignant) 03/01/2020 - "To investigate efficacy of masitinib mesylate for the treatment of advanced malignant melanoma in dogs. " 03/01/2020 - "There was only mild effectiveness in end-stage disease, indicating that masitinib mesylate is not an appropriate sole-agent option for treatment of advanced malignant melanoma in dogs." 03/01/2020 - "Prospective clinical trial of masitinib mesylate treatment for advanced stage III and IV canine malignant melanoma." 12/01/2015 - "This report corroborates the plausibility of treating advanced melanoma carrying a mutation of KIT with masitinib. " 12/01/2015 - "Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases: A case report."

Related Drugs and Biologics

1.	Adrenal Cortex Hormones (Corticosteroids)
2.	Proteins (Proteins, Gene)
3.	Creatinine
4.	Hepatitis A Antibodies
5.	Tyrosine Kinase Inhibitors
6.	Gemcitabine
7.	masitinib
8.	Therapeutic Uses
9.	Memantine (Namenda)
10.	Doxorubicin (Adriamycin)

Related Therapies and Procedures

1.	Therapeutics
2.	Aftercare (After-Treatment)
3.	Bone Marrow Transplantation (Transplantation, Bone Marrow)
4.	Tourniquets
5.	Activities of Daily Living (ADL)